BR0317717A - Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto - Google Patents

Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto

Info

Publication number
BR0317717A
BR0317717A BR0317717-3A BR0317717A BR0317717A BR 0317717 A BR0317717 A BR 0317717A BR 0317717 A BR0317717 A BR 0317717A BR 0317717 A BR0317717 A BR 0317717A
Authority
BR
Brazil
Prior art keywords
compound
disease
preparation
pharmaceutical composition
treating
Prior art date
Application number
BR0317717-3A
Other languages
English (en)
Other versions
BRPI0317717B8 (pt
BRPI0317717B1 (pt
Inventor
Nicola Murdoch Heron
Frederic Henri Jung
Georges Rene Pasquet
Andrew Austen Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0317717A publication Critical patent/BR0317717A/pt
Publication of BRPI0317717B1 publication Critical patent/BRPI0317717B1/pt
Publication of BRPI0317717B8 publication Critical patent/BRPI0317717B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODO PARA TRATAR UM HUMANO SOFRENDO DE UMA DOENçA, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO. Derivados de quinazolina de Fórmula(I), em que A é hereroarila de 5-membros, contendo um átomo de nitrogênio e um ou dois átomos de nitrogênio adicionais; composições contendo-os, processos para sua preparação e seu uso em terapia.
BRPI0317717A 2002-12-24 2003-12-22 composto, composição farmacêutica, e uso de um composto BRPI0317717B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP02293238.8 2002-12-24
EP03291315 2003-06-02
EP03291315.4 2003-06-02
PCT/GB2003/005613 WO2004058781A1 (en) 2002-12-24 2003-12-22 Phosphonooxy quinazoline derivatives and their pharmaceutical use

Publications (3)

Publication Number Publication Date
BR0317717A true BR0317717A (pt) 2005-11-22
BRPI0317717B1 BRPI0317717B1 (pt) 2017-12-19
BRPI0317717B8 BRPI0317717B8 (pt) 2021-05-25

Family

ID=32683824

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0317717A BRPI0317717B8 (pt) 2002-12-24 2003-12-22 composto, composição farmacêutica, e uso de um composto

Country Status (30)

Country Link
US (4) US7528121B2 (pt)
EP (2) EP1578755B1 (pt)
JP (3) JP4422102B2 (pt)
KR (1) KR101010299B1 (pt)
AR (2) AR042668A1 (pt)
AT (2) ATE438644T1 (pt)
AU (1) AU2003290313B2 (pt)
BR (1) BRPI0317717B8 (pt)
CA (1) CA2511613C (pt)
CL (1) CL2003002731A1 (pt)
CY (2) CY1107775T1 (pt)
DE (2) DE60315892T2 (pt)
DK (2) DK1847539T3 (pt)
ES (2) ES2290529T3 (pt)
HK (2) HK1080481A1 (pt)
IL (2) IL169112A (pt)
IS (2) IS2504B (pt)
MX (1) MXPA05006918A (pt)
MY (2) MY136174A (pt)
NO (2) NO335193B1 (pt)
NZ (1) NZ540698A (pt)
PL (2) PL223998B1 (pt)
PT (2) PT1578755E (pt)
RU (3) RU2357971C2 (pt)
SA (1) SA04240504B1 (pt)
SI (2) SI1847539T1 (pt)
TW (2) TWI393710B (pt)
UA (1) UA83814C2 (pt)
UY (1) UY28149A1 (pt)
WO (1) WO2004058781A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471577C (en) * 2001-12-24 2011-08-02 Astrazeneca Ab Chemical compounds
AU2003290322A1 (en) * 2002-12-24 2004-07-22 Astrazeneca Ab Quinazoline compounds
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
ATE390422T1 (de) * 2003-04-16 2008-04-15 Astrazeneca Ab Quinazolin-derivate für die behandling von krebs
MXPA05012377A (es) * 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
EP1802608A1 (en) * 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
ATE540935T1 (de) 2004-10-12 2012-01-15 Astrazeneca Ab Chinazolinderivate
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1809636A1 (en) * 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2009111028A1 (en) * 2008-03-04 2009-09-11 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
DK2276346T3 (en) 2008-04-30 2017-02-27 Nat Health Research Institutes FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS
EA201100126A1 (ru) * 2008-07-03 2011-08-30 Мерк Патент Гмбх Нафтиридиноны в качестве ингибиторов протеинкиназ
CA2744713A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
CA2746652C (en) 2008-12-11 2018-03-06 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
EP2958911B1 (en) 2013-02-21 2017-10-18 GlaxoSmithKline Intellectual Property Development Limited Quinazolines as kinase inhibitors
RU2682332C2 (ru) * 2013-09-16 2019-03-19 Астразенека Аб Терапевтические полимерные наночастицы и способы их получения и применения
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
AU2018330188C1 (en) 2017-09-08 2024-02-29 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 inhibitors and their use for the treatment of cancer
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1995033724A1 (en) 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2239692C (en) 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
CN1161352C (zh) 1998-10-08 2004-08-11 阿斯特拉曾尼卡有限公司 喹唑啉衍生物
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
PL360439A1 (en) * 2000-06-28 2004-09-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
EP1301497A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1408980A4 (en) * 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
CA2471577C (en) * 2001-12-24 2011-08-02 Astrazeneca Ab Chemical compounds
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
AU2003290322A1 (en) * 2002-12-24 2004-07-22 Astrazeneca Ab Quinazoline compounds
ATE390422T1 (de) * 2003-04-16 2008-04-15 Astrazeneca Ab Quinazolin-derivate für die behandling von krebs

Also Published As

Publication number Publication date
IS7948A (is) 2005-07-20
NO335193B1 (no) 2014-10-20
CA2511613C (en) 2012-10-02
EP1578755A1 (en) 2005-09-28
SI1578755T1 (sl) 2007-12-31
RU2357971C2 (ru) 2009-06-10
TWI336327B (en) 2011-01-21
NO20052855D0 (no) 2005-06-13
RU2007121850A (ru) 2008-12-20
EP1847539A1 (en) 2007-10-24
US20060116357A1 (en) 2006-06-01
NO20052855L (no) 2005-08-03
NO335446B1 (no) 2014-12-15
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
JP2009046514A (ja) 2009-03-05
CA2511613A1 (en) 2004-07-15
WO2004058781A1 (en) 2004-07-15
NZ540698A (en) 2008-05-30
US9567358B2 (en) 2017-02-14
PT1578755E (pt) 2007-10-19
SA04240504B1 (ar) 2008-04-01
US20150307534A1 (en) 2015-10-29
JP4422102B2 (ja) 2010-02-24
BRPI0317717B8 (pt) 2021-05-25
US20140162984A1 (en) 2014-06-12
IL169112A0 (en) 2009-02-11
AU2003290313B2 (en) 2007-05-10
EP1578755B1 (en) 2007-08-22
US8268841B2 (en) 2012-09-18
AU2003290313A1 (en) 2004-07-22
RU2005123485A (ru) 2006-03-10
DK1847539T3 (da) 2009-11-09
IS2504B (is) 2009-04-15
DE60315892D1 (de) 2007-10-04
IL185176A (en) 2011-10-31
PT1847539E (pt) 2009-10-06
HK1080481A1 (en) 2006-04-28
UY28149A1 (es) 2004-07-30
CL2003002731A1 (es) 2005-01-07
PL377680A1 (pl) 2006-02-06
TWI393710B (zh) 2013-04-21
DK1578755T3 (da) 2007-11-12
ATE370958T1 (de) 2007-09-15
US20100069412A1 (en) 2010-03-18
MXPA05006918A (es) 2005-08-18
NO20131444L (no) 2005-08-03
KR20050088333A (ko) 2005-09-05
JP2007326862A (ja) 2007-12-20
PL412704A1 (pl) 2015-10-12
ES2290529T3 (es) 2008-02-16
PL223998B1 (pl) 2016-11-30
TW200510342A (en) 2005-03-16
BRPI0317717B1 (pt) 2017-12-19
EP1847539B1 (en) 2009-08-05
CY1109479T1 (el) 2014-08-13
UA83814C2 (ru) 2008-08-26
US7528121B2 (en) 2009-05-05
HK1111417A1 (en) 2008-08-08
ES2329623T3 (es) 2009-11-27
SI1847539T1 (sl) 2010-01-29
IL185176A0 (en) 2007-12-03
CY1107775T1 (el) 2013-06-19
IS8714A (is) 2008-02-13
KR101010299B1 (ko) 2011-01-25
IS2884B (is) 2014-06-15
SA04240504A (ar) 2005-12-03
MY147761A (en) 2013-01-31
ATE438644T1 (de) 2009-08-15
JP2006512418A (ja) 2006-04-13
MY136174A (en) 2008-08-29
RU2350611C1 (ru) 2009-03-27
TW201102369A (en) 2011-01-16
DE60328735D1 (de) 2009-09-17
US9018191B2 (en) 2015-04-28
JP4906608B2 (ja) 2012-03-28
IL169112A (en) 2010-12-30
JP4503090B2 (ja) 2010-07-14
PL221490B1 (pl) 2016-04-29
DE60315892T2 (de) 2008-08-14

Similar Documents

Publication Publication Date Title
BR0317717A (pt) Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto
BR0317680A (pt) Composto, composição farmacêutica, uso de um composto, ou de um sal farmaceuticamente aceitável do mesmo, método de tratamento de um ser humano, e, processo para a preparação de um composto
BR0115446A (pt) Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BRPI0512253A (pt) composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BRPI0418351A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9915420A (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BR0312464A (pt) Inibidores de tirosina quinases
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0113042A (pt) Composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivìduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BRPI0514036A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF